文献速递头颈CTPET

头颈癌患者放疗期间有无剂量绘画提升的剂量分布比较:基于螺旋断层治疗机的实现

Comparison of dose distribution for head and neck cancer patients with and without dose painting escalation during radiotherapy realized with tomotherapy unit.
PubMed 文献 · Br J Radiol · 2017-06-23

回顾性纳入12例接受18F-FDG PET/CT扫描的头颈癌患者,为每例分别优化有无剂量绘画提升的两套治疗计划。剂量绘画提升使所有危及器官剂量升高3.0%至12.9%(腮腺增幅最大、下颌骨最小),但通常未超过剂量耐受水平;束流开启时间无显著差异。作者认为多级剂量绘画提升对约83%患者可行且不增加毒性,但需更大样本临床试验确认。

要点

  • 多级剂量绘画提升使危及器官剂量升高3.0%至12.9%,腮腺增幅最大、下颌骨最小。
  • 仅有脑干和下颌骨V60Gy两处例外,其余危及器官剂量均显著升高。
  • 有无剂量绘画提升计划的束流开启时间无统计学显著差异。

核心结论

  • 剂量绘画提升虽使危及器官剂量高于常规治疗计划,但通常未超过剂量耐受水平;作者认为多级剂量绘画提升至很高剂量对约83%患者可行且不增加毒性,但需临床试验确认获益并保证无额外毒性,且需在更大患者群体中验证。

研究设计与样本

  • 回顾性纳入12例接受18F-FDG PET/CT扫描的头颈癌患者,基于PET/CT数据为每例优化有无剂量绘画提升的两套治疗计划,比较危及器官剂量、靶区体积、执行时间、等效均匀剂量和正常组织并发症概率。

诊断标准与关键数值

  • 多级剂量绘画提升使危及器官剂量升高3.0%至12.9%,具体增幅取决于危及器官。
  • 腮腺剂量增幅最大,下颌骨剂量增幅最小。
  • 仅脑干和下颌骨V60Gy两处例外,其余所有剂量绘画提升计划的危及器官剂量均显著升高。

临床应用与阅片要点

  • 作者认为多级剂量绘画提升至很高剂量对约83%患者可行且不增加毒性,但需更大样本确认。
  • 作者指出需临床试验确认剂量绘画提升的获益并保证无额外毒性。

局限性

  • 原文指出需临床试验确认剂量绘画提升的获益并保证无额外毒性。
  • 原文指出剂量绘画提升至很高剂量对约83%患者可行的发现仍需在更大患者群体中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To determine and quantify the percentage dose increase to organs at risk (OARs) with multiple-level dose painting (DP) for patients with head and neck cancer in comparison with standard regimen.

METHODS: 12 patients who had undergone fluorine-18 fludeoxyglucose (18F-FDG) positron emission tomography (PET)/CT scan were retrospectively enrolled. Two treatment plans-one using DP escalation and one without-were optimized for each patient base on PET/CT data. The following variables were assessed: dose to OARs and target volumes; execution time; equivalent uniform dose; and normal tissue complication probability.

RESULTS: No statistically significant differences in beam-on time were observed between plans with and without DP. However, significantly higher doses were observed for all DP-escalated plans in the OARs, with only two exceptions: the brain stem and V60Gy for the mandible. Multiple-level DP resulted in dose increases ranging from 3.0% to 12.9%, depending on the OAR. The largest increase was seen for the parotid glands and the smallest for the mandible. Significant differences in the equivalent uniform dose were observed only for the parotid glands and spinal column, where the dose without DP was lower. The normal tissue complication probability for most OARs was very small.

CONCLUSION: Importantly, even though DP escalation resulted in higher doses to OARs vs conventional treatment planning, these usually did not exceed the dose tolerance levels. However, clinical trials are necessary to confirm the benefits of DP and to guarantee no additional toxicity. Advances in knowledge: Multiple-level DP by numbers resulted in 3.0-12.9% dose increase, depending on the OAR. Our findings may suggest that DP escalation to very high doses is feasible for about 83% of patients without higher toxicity; however, it still should be confirmed on a larger group of patients.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Skorska M, Piotrowski T, Ryczkowski A, et al. Comparison of dose distribution for head and neck cancer patients with and without dose painting escalation during radiotherapy realized with tomotherapy unit. Br J Radiol. 2017. PMID: 28555505. doi:10.1259/bjr.20170019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。